文献速递肝病

磁共振成像生物标志物识别高风险进展非酒精性脂肪性肝炎患者的临床效用:多中心汇总数据与荟萃分析

Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-10-07

该研究汇总5项临床研究共543例疑似非酒精性脂肪性肝病(NAFLD)患者数据,评估校正T1(cT1)与磁共振成像(MRI)肝脏脂肪定量识别非酒精性脂肪性肝炎(NASH)及高风险NASH(NAFLD活动度评分≥4且纤维化分期≥2)的准确性。结果显示cT1识别NASH的AUROC为0.78,识别高风险NASH的AUROC为0.78,优于MRI肝脏脂肪的0.69;cT1联合肝脏脂肪识别NASH的AUROC为0.82。结论认为cT1是识别进展风险最高NASH患者较好的无创技术。

要点

  • cT1识别NASH的AUROC为0.78,与MRI肝脏脂肪相当。
  • cT1识别高风险NASH的AUROC为0.78,优于MRI肝脏脂肪的0.69。
  • cT1联合MRI肝脏脂肪识别NASH的AUROC为0.82。

核心结论

  • 定量MRI衍生生物标志物cT1和肝脏脂肪均适用于识别NASH患者。
  • cT1在识别疾病进展风险最高的NASH患者方面优于肝脏脂肪。
  • MRI cT1和肝脏脂肪有助于指导NAFLD和NASH临床诊疗路径中干预措施的合理使用。

研究设计与样本

  • 汇总5项临床研究共543例疑似NAFLD患者的数据,并进行个体参与者数据荟萃分析。
  • 采用受试者工作特征曲线下面积(AUROC)评估MRI生物标志物对NASH患者分层的诊断准确性。

主要发现

  • cT1和MRI肝脏脂肪随NAFLD严重程度增加呈逐步升高,且cT1在高风险NASH参与者中显著更高。
  • cT1识别NASH的AUROC为0.78(95%CI 0.74-0.82),MRI肝脏脂肪为0.78(95%CI 0.73-0.82),两者联合为0.82(95%CI 0.78-0.85)。
  • cT1识别高风险NASH的AUROC为0.78(95%CI 0.74-0.82),优于MRI肝脏脂肪的0.69(95%CI 0.64-0.74)。
  • cT1联合MRI肝脏脂肪识别高风险NASH的AUROC为0.79(95%CI 0.75-0.83),未见大幅提升。
  • 荟萃分析显示这些生物标志物的性能与汇总分析相似。

临床怎么用

  • cT1和MRI肝脏脂肪可作为无创工具用于识别NASH患者。
  • cT1可优先用于识别进展风险最高的NASH患者,以指导临床干预决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. NAFLD is associated with excess risk of all-cause mortality, and its progression to nonalcoholic steatohepatitis (NASH) and fibrosis accounts for a growing proportion of cirrhosis and hepatocellular cancer and thus is a leading cause of liver transplant worldwide. Noninvasive precise methods to identify patients with NASH and NASH with significant disease activity and fibrosis are crucial when the disease is still modifiable. The aim of this study was to examine the clinical utility of corrected T1 (cT1) vs magnetic resonance imaging (MRI) liver fat for identification of NASH participants with nonalcoholic fatty liver disease activity score ≥4 and fibrosis stage (F) ≥2 (high-risk NASH). METHODS: Data from five clinical studies (n = 543) with participants suspected of NAFLD were pooled or used for individual participant data meta-analysis. The diagnostic accuracy of the MRI biomarkers to stratify NASH patients was determined using the area under the receiver operating characteristic curve (AUROC). RESULTS: A stepwise increase in cT1 and MRI liver fat with increased NAFLD severity was shown, and cT1 was significantly higher in participants with high-risk NASH. The diagnostic accuracy (AUROC) of cT1 to identify patients with NASH was 0.78 (95% CI, 0.74-0.82), for liver fat was 0.78 (95% CI, 0.73-0.82), and when combined with MRI liver fat was 0.82 (95% CI, 0.78-0.85). The diagnostic accuracy of cT1 to identify patients with high-risk NASH was good (AUROC = 0.78; 95% CI, 0.74-0.82), was superior to MRI liver fat (AUROC = 0.69; 95% CI, 0.64-0.74), and was not substantially improved by combining it with MRI liver fat (AUROC = 0.79; 95% CI, 0.75-0.83). The meta-analysis showed similar performance to the pooled analysis for these biomarkers. CONCLUSIONS: This study shows that quantitative MRI-derived biomarkers cT1 and liver fat are suitable for identifying patients with NASH, and cT1 is a better noninvasive technology than liver fat to identify NASH patients at greatest risk of disease progression. Therefore, MRI cT1 and liver fat have important clinical utility to help guide the appropriate use of interventions in NAFLD and NASH clinical care pathways.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Andersson A, Kelly M, Imajo K, et al. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clin Gastroenterol Hepatol. 2021. PMID: 34626833. doi:10.1016/j.cgh.2021.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。